Corcept Therapeutics (CORT) Investor Alert: April 21 Deadline Approaches in Securities Fraud Case

Investors Who Purchased CORCEPT Stock May Have Limited Time to Act

Investors who purchased shares of Corcept Therapeutics Incorporated may have only days remaining to take action as a key deadline approaches in a pending securities fraud class action.

According to recently filed litigation, the case alleges that Corcept and certain executives made materially misleading statements and omissions regarding the company’s flagship drug candidate, relacorilant, particularly in connection with regulatory communications and clinical development risks. Source: www.prnewswire.com/news-releases/cort-alert-hagens-berman-alerts-corcept-therapeutics-cort-investors-to-approaching-april-21st-lead-plaintiff-deadline-in-securities-fraud-class-action-over-relacorilant-failure-302740940.html

The lawsuit is currently pending in the U.S. District Court for the Northern District of California and seeks to recover losses on behalf of investors who acquired Corcept securities during the proposed class period.

Allegations Focus on FDA-Related Disclosures

At the center of the case are allegations that Corcept failed to adequately disclose risks tied to its interactions with the U.S. Food and Drug Administration, including issues that may have impacted the regulatory pathway and commercial outlook for relacorilant.

Investors allege that the company’s public statements painted an overly optimistic picture of the drug’s development and approval prospects, while omitting or downplaying known regulatory challenges. When the truth began to emerge, the complaint alleges, investors suffered significant losses.

Class Period and Lead Plaintiff Deadline

The proposed class includes investors who purchased Corcept securities between October 31, 2024 and December 30, 2025. A critical deadline is now approaching.

Lead Plaintiff Deadline: April 21, 2026 – PR Newswire

Investors who suffered losses during the class period may have the ability to seek appointment as lead plaintiff, a role that allows participation in directing the litigation and representing the interests of other affected investors.

Why This Case Matters

Cases involving pharmaceutical companies often hinge on whether investors were properly informed of regulatory risks. The FDA approval process is highly technical and can materially impact a company’s valuation.

When companies allegedly fail to disclose meaningful regulatory obstacles or uncertainties, it can expose investors to unexpected downside risk once corrective information reaches the market.

What Affected Investors Should Consider

Investors who purchased Corcept stock during the class period should consider:

• Whether they incurred losses tied to price declines following disclosures
• The potential benefits of participating in the class action
• The approaching April 21, 2026 deadline to seek lead plaintiff status

Even investors who do not seek lead plaintiff status may still be eligible to participate in any potential recovery.

Sonn Law Group Is Investigating

Sonn Law Group is actively reviewing potential claims on behalf of investors who suffered losses in Corcept Therapeutics. If you invested in Corcept Therapeutics and experienced losses, you may be entitled to compensation.

Contact Sonn Law Group

To learn more about your rights or to discuss a potential claim, contact Sonn Law Group for a confidential consultation.